ADORA2A and neoplasm: Preclinical research has also shown that PBF-509, a novel A2AR antagonist, significantly boosts the immune response of tumor-infiltrating lymphocytes and reduces tumor metastasis, either alone or in combination with anti-PD-1/PD-L1 [169].